Announce pivotal development plan for mitapivat in sickle cell disease
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Checked
- 24 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Announce pivotal development plan for mitapivat in adults with sickle cell disease in the first half of 2021”
What we found
Evidence strength A What the grades mean
The company did not announce the pivotal development plan by the first half of 2021; subsequent filings indicate the initiation of the trial was pushed to the end of 2021.
-
A Agios Pharmaceuticals, Inc. 8-K filed 2021-07-29
“Initiate Phase 2/3 study of mitapivat in sickle cell disease by year-end.” ✓ confirmed on the page
-
A Agios Pharmaceuticals, Inc. 10-Q filed 2021-07-29
“A phase 2/3 trial of mitapivat in patients with SCD, which we expect to initiate by the end of 2021.” ✓ confirmed on the page
Market reaction: the shares moved -3.3% against the S&P 500 over the three sessions around the disclosure (28 Jul 2021 to 2 Aug 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Announce
- Deliverable
- Pivotal development plan for mitapivat
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Agios Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AGIO-021569 · Corrections policy